Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the Betaplus Program
Latest Information Update: 20 Jan 2015
Price :
$35 *
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SEPLUS
- Sponsors Bayer
- 28 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2014 Planned End Date changed from 1 Apr 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 08 Apr 2014 Planned End Date changed from 1 Feb 2014 to 1 Apr 2014, as per ClinicalTrials.gov record.